

INTRATHECAL THERAPY

Evaluating the Evidence

A Continuing Education Breakfast Symposium
Held during the 18th National Conference of the American Society for Pain Management Nursing

Friday, September 5, 2008

7:40–9:10 AM

The JW Marriott Starr Pass Resort
Arizona Salons 7-12, Second Floor
Tucson, Arizona

Chair

Anne Sapienza-Crawford, RN, MSN, CNP
Nurse Practitioner
Cleveland Clinic Foundation
Cleveland, Ohio

Faculty

Sharon Fiekowsky, RN, MSN, NP-C
Certified Nurse Practitioner
Consultant/Research Nurse
Los Altos, California

Lisa J. Stearns, MD
Medical Director, Supportive Care
Scottsdale Healthcare
Scottsdale, Arizona

Program

7:40 AM	Opening Comments and Objectives Anne Sapienza-Crawford, RN, MSN, CNP
7:45 AM	2007 Polyanalgesic Consensus Conference IT Treatment Algorithm Lisa J. Stearns, MD
8:10 AM	Options for Intrathecal Trialing Anne Sapienza-Crawford, RN, MSN, CNP
8:35 AM	Complications of Intrathecal Therapy Sharon Fiekowsky, RN, MSN, NP-C
9:00 AM	Questions and Answers
9:10 AM	Closing Comments/Adjourn

AMERICAN SOCIETY FOR
Pain Management
Nursing

MedLogix
Communications, LLC

This activity is jointly sponsored by the American Society for Pain Management Nursing and MedLogix Communications, LLC.

élan

This symposium is supported through an unrestricted educational grant from Elan Pharmaceuticals, Inc., in accordance with ASPMN policy.

INTRATHECAL THERAPY Evaluating the Evidence

Educational Overview

The 2007 Polyanalgesic Consensus Conference (PACC) expert panel proposed new clinical practice guidelines and a corresponding algorithm for intrathecal (IT) drug selection based on recent scientific and clinical evidence. The agents in the evidence-based algorithm were tiered on the basis of the expert opinions of the PACC panel members and on safety/tolerability, efficacy, and other clinical parameters from published literature. Patient responsiveness to IT therapy is typically evaluated by an external pump trial before long-term IT therapy is initiated. Various trialing protocols have been implemented in clinical practice, but a trial method consensus has not yet been established. Several factors need to be taken into consideration when a trialing protocol is chosen, including patient condition, available resources, and clinical environment. Complications of IT therapy include drug-related adverse events, procedure-related complications, and equipment-related problems. Proper monitoring of the patient by health care professionals and management of patient expectations through education are imperative for successful treatment.

Learning Objectives

At the conclusion of this symposium, the participant should be able to

- Summarize the recommended 2007 PACC IT treatment algorithm
- Identify appropriate options for trialing IT therapy
- Describe complications associated with IT therapy

Target Audience

This course was designed for nurses and other health care professionals with an interest in pain management through IT therapy.

Accreditation

This continuing nursing education activity has been submitted to the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

Credit Designation

The American Society for Pain Management Nursing (ASPMN) designates this educational activity for a maximum of 1.0 CE contact hours.

Faculty Disclosure

In accordance with Policy, presenters have indicated if they have a conflict of interest, and if so, it has been resolved.

Registration

To register, please visit the conference Web site at www.aspmn.org/Conference/index.htm.

ADA Statement

The ASPMN fully intends to comply with the legal requirements of the Americans with Disabilities Act. If any participant of this program is in need of accommodation, please do not hesitate to contact Amy Borley of MedLogix Communications at 847-413-1445.

Vested Interest

The contents of some CE presentations may contain discussions of non-approved or off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Dissemination Statement

The ASPMN has authorized Elan Pharmaceuticals, Inc., to disseminate this program announcement to the medical community.